Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists
US11718680B2 · kind B2 · utility
2Cited by
10References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2020 |
| Grant date | Aug 8, 2023 |
| Priority date | — |
| Expiry date | Oct 16, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/75
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to combination therapies employing anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.